Impact of COVID-19 and lockdowns on pulmonary embolism in hospitalized patients in France: a nationwide study.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
20 Nov 2021
Historique:
received: 30 08 2021
accepted: 03 11 2021
entrez: 21 11 2021
pubmed: 22 11 2021
medline: 15 12 2021
Statut: epublish

Résumé

This study assessed the impact of the COVID-19 epidemic on overall hospitalizations for pulmonary embolism (PE) in France in comparison with previous years, and by COVID-19 and non-COVID-19 status. Hospitalization data (2017-2020) were extracted from the French National Discharge database (all public and private hospitals). We included all patients older than 18 years hospitalized during the 3 years and extracted PE status and COVID-19 status (from March 2020). Age, sex and risk factors for PE (such as obesity, cancer) were identified. We also extracted transfer to an intensive care unit (ICU) and hospital death. The number of PE and the frequency of death in patients in 2019 and 2020 were described by month and by COVID-19 status. Logistic regressions were performed to identify the role of COVID-19 among other risk factors for PE in hospitalized patients. The overall number of patients hospitalized with PE increased by about 16% in 2020 compared with 2019, and mortality also increased to 10.3% (+ 1.2%). These increases were mostly linked to COVID-19 waves, which were associated with PE hospitalization in COVID-19 patients (PE frequency was 3.7%; 2.8% in non-ICU and 8.8% in ICU). The final PE odds ratio for COVID-19 hospitalized patients was 4 compared with other hospitalized patients in 2020. The analyses of PE in non-COVID-19 patients showed a 2.7% increase in 2020 compared with the previous three years. In 2020, the overall number of patients hospitalized with PE in France increased compared to the previous three years despite a considerable decrease in scheduled hospitalizations. Nevertheless, proactive public policy focused on the prevention of PE in all patients should be encouraged.

Sections du résumé

BACKGROUND BACKGROUND
This study assessed the impact of the COVID-19 epidemic on overall hospitalizations for pulmonary embolism (PE) in France in comparison with previous years, and by COVID-19 and non-COVID-19 status.
METHODS METHODS
Hospitalization data (2017-2020) were extracted from the French National Discharge database (all public and private hospitals). We included all patients older than 18 years hospitalized during the 3 years and extracted PE status and COVID-19 status (from March 2020). Age, sex and risk factors for PE (such as obesity, cancer) were identified. We also extracted transfer to an intensive care unit (ICU) and hospital death. The number of PE and the frequency of death in patients in 2019 and 2020 were described by month and by COVID-19 status. Logistic regressions were performed to identify the role of COVID-19 among other risk factors for PE in hospitalized patients.
RESULTS RESULTS
The overall number of patients hospitalized with PE increased by about 16% in 2020 compared with 2019, and mortality also increased to 10.3% (+ 1.2%). These increases were mostly linked to COVID-19 waves, which were associated with PE hospitalization in COVID-19 patients (PE frequency was 3.7%; 2.8% in non-ICU and 8.8% in ICU). The final PE odds ratio for COVID-19 hospitalized patients was 4 compared with other hospitalized patients in 2020. The analyses of PE in non-COVID-19 patients showed a 2.7% increase in 2020 compared with the previous three years.
CONCLUSION CONCLUSIONS
In 2020, the overall number of patients hospitalized with PE in France increased compared to the previous three years despite a considerable decrease in scheduled hospitalizations. Nevertheless, proactive public policy focused on the prevention of PE in all patients should be encouraged.

Identifiants

pubmed: 34801044
doi: 10.1186/s12931-021-01887-6
pii: 10.1186/s12931-021-01887-6
pmc: PMC8605779
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

298

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-20-COV1-0005-01

Informations de copyright

© 2021. The Author(s).

Références

Can J Public Health. 2020 Dec;111(6):995-999
pubmed: 33052586
Anesthesiology. 2021 Mar 1;134(3):457-467
pubmed: 33417674
PLoS One. 2021 Mar 3;16(3):e0248008
pubmed: 33657182
Clin Radiol. 2021 Apr;76(4):310-312
pubmed: 33610286
J Clin Med. 2021 Feb 14;10(4):
pubmed: 33672837
Am J Cardiovasc Dis. 2020 Oct 15;10(4):432-443
pubmed: 33224594
Br J Surg. 2020 Aug;107(9):e300
pubmed: 32506419
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Eur Heart J. 2021 Aug 31;42(33):3127-3142
pubmed: 34164664
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Lancet. 2021 Jun 12;397(10291):2253-2263
pubmed: 34097856
Res Pract Thromb Haemost. 2020 Oct 13;4(7):1178-1191
pubmed: 33043231
Chest. 2021 Mar;159(3):1182-1196
pubmed: 33217420
Crit Care Explor. 2020 Dec 17;2(12):e0308
pubmed: 33364605
Rev Epidemiol Sante Publique. 2017 Aug;65(4):321-325
pubmed: 28576381
Res Pract Thromb Haemost. 2020 Jun 25;4(5):835-841
pubmed: 32685892
Fundam Clin Pharmacol. 2018 Feb;32(1):108-113
pubmed: 29055145
Am J Pathol. 1983 Jul;112(1):112-26
pubmed: 6859225
Lancet Respir Med. 2021 Mar;9(3):251-259
pubmed: 33341155
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621996471
pubmed: 33689493
Stroke. 2021 Apr;52(4):1362-1369
pubmed: 33626900
Thromb Res. 2021 Jun;202:17-23
pubmed: 33711754
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
J Educ Health Promot. 2021 Jan 28;10:28
pubmed: 33688537
J Vasc Surg Venous Lymphat Disord. 2021 Sep;9(5):1099-1111.e6
pubmed: 33529719
Thromb Res. 2021 Mar;199:97-100
pubmed: 33485095
Shock. 2021 Jun 1;55(6):700-716
pubmed: 33378321
Glob Health Med. 2021 Apr 30;3(2):122-124
pubmed: 33937578
Radiology. 1987 Apr;163(1):57-66
pubmed: 3823457
Eur Respir J. 2021 Jul 20;58(1):
pubmed: 33692122
Radiology. 2021 Feb;298(2):E70-E80
pubmed: 33320063
Ann Intensive Care. 2020 Sep 16;10:124
pubmed: 32953201
Insights Imaging. 2021 Feb 17;12(1):24
pubmed: 33595746
Cochrane Database Syst Rev. 2021 Mar 11;3:CD013879
pubmed: 33704775
Lancet Public Health. 2020 Oct;5(10):e536-e542
pubmed: 32950075

Auteurs

Pierre Tankere (P)

Reference Center for Rare Pulmonary Diseases, Pulmonary Medicine and Intensive Care Unit Department, Dijon University Hospital, BP 77908, 21079, Dijon, France.

Jonathan Cottenet (J)

CHU de Dijon - Service de Biostatistique et d'Informatique Médicale, BP 77908, 21079, Dijon CEDEX, France.
University of Burgundy and Franche-Comté, Dijon, France.

Pascale Tubert-Bitter (P)

Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, High-Dimensional Biostatistics for Drug Safety and Genomics, CESP, Villejuif, France.

Anne-Sophie Mariet (AS)

CHU de Dijon - Service de Biostatistique et d'Informatique Médicale, BP 77908, 21079, Dijon CEDEX, France.
University of Burgundy and Franche-Comté, Dijon, France.
Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, Inserm, CIC 1432, Dijon, France ; Dijon University Hospital, Dijon, France.

Guillaume Beltramo (G)

Reference Center for Rare Pulmonary Diseases, Pulmonary Medicine and Intensive Care Unit Department, Dijon University Hospital, BP 77908, 21079, Dijon, France.

Jacques Cadranel (J)

Chest Department and Constitutive Center for Rare Pulmonary Disease, Hôpital Tenon, AP-HP, Inflammation-Immunopathology-Biotherapy Department (DHU i2B) and Sorbonne Université, 75020, Paris, France.

Lionel Piroth (L)

Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, Inserm, CIC 1432, Dijon, France ; Dijon University Hospital, Dijon, France.
Faculty of Medicine, University of Burgundy and Franche-Comté, Dijon, France.
Infectious Diseases Department, Dijon University Hospital, BP 77908, 21079, Dijon, France.

Philippe Bonniaud (P)

Reference Center for Rare Pulmonary Diseases, Pulmonary Medicine and Intensive Care Unit Department, Dijon University Hospital, BP 77908, 21079, Dijon, France.
Faculty of Medicine, University of Burgundy and Franche-Comté, Dijon, France.
INSERM, LNC UMR1231, LipSTIC LabEx Team, Dijon, France.

Catherine Quantin (C)

CHU de Dijon - Service de Biostatistique et d'Informatique Médicale, BP 77908, 21079, Dijon CEDEX, France. catherine.quantin@chu-dijon.fr.
University of Burgundy and Franche-Comté, Dijon, France. catherine.quantin@chu-dijon.fr.
Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, High-Dimensional Biostatistics for Drug Safety and Genomics, CESP, Villejuif, France. catherine.quantin@chu-dijon.fr.
Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, Inserm, CIC 1432, Dijon, France ; Dijon University Hospital, Dijon, France. catherine.quantin@chu-dijon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH